Guggenheim analyst Yatin Suneja raised the firm’s price target on Neurocrine (NBIX) to $175 from $165 and keeps a Buy rating on the shares. Non-GAAP EPS came in above the Street’s forecast and the company narrowed FY25 Ingrezza sales guidance to $2.5-$2.55B, notes the analyst, who calls out the Phase 2 readout in MDD with NBI-770 and Phase 3 readouts in Dyskinetic Cerebral Palsy, both due in Q4, as the next key catalysts for Neurocrine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences’ Earnings Call Highlights Growth
- Neurocrine price target raised to $175 from $154 at Piper Sandler
- Neurocrine price target raised to $186 from $180 at Baird
- Neurocrine price target raised to $170 from $165 at TD Cowen
- Neurocrine price target raised to $141 from $137 at Wedbush